Avsnitt
-
Conversation around the barriers to GLP-1 RAS. Dr. Trudy Gaillard and Dr. Monica Peek discuss adverse effects, cost, strategies when taking with other medications, social determinants of health, and educational support.
Claim CE and MOC Credit at https://bit.ly/4bmIxu0
-
Saknas det avsnitt?
-
Conversation around patient selection and GLP-1 RAs. The speakers will explore the effects of GLP-1 RAs and SGLT-2 inhibitors on clinical outcomes and CVD risk factors.
Claim CE Credit at https://bit.ly/4aSgdzz -
It has been essential for healthcare professionals to be responsive to emerging knowledge from the scientific community to manage patients contracting the SARS-CoV-2 illness. Dr. Jeff Hsu talks with Dr. Carrie Harvey about the cardiovascular risks with COVID-19, diagnostic tools, clinical manifestations, short and long-term cardiovascular outcomes after recovery from the acute infection. Recommendations for cardiac wellness will also be discussed. Claim CE and MOC Credit at https://bit.ly/3QISie3
-
In this episode, a panel of experts discuss existing VTE treatment options, algorithms, corresponding safety and efficacy profiles along with safety and efficacy data, and protocols to address treatment pathways.
Claim CE and MOC Credit at https://bit.ly/VTEIII
-
COVID-19 care is now mostly provided outside of hospital settings. Early diagnosis and therapeutic intervention for those who are at increased risk of progression to severe COVID-19 may improve outcomes. Dr. Jeff Hsu talks with Dr. Mary Brennan about the symptoms associated with the different stages of SARS-CoV-2 and choosing the appropriate outpatient therapeutic treatment.
CE and ABIM MOC credits available: https://bit.ly/3PeZRIy
-
Conversation about the approved GLP-1 RAs to manage type 2 diabetes mellitus (T2DM). Forms of administration, contextualizing the many benefits and the risks, and indications will be discussed.
Claim CE Credit at https://bit.ly/49Ultlu
-
Conversation about the global rise of obesity and its association with diabetes and the limited effectiveness of many pharmacotherapies tested for management of obesity. You will also learn about weight loss benefits, improvement in cardiovascular risk factors, and potential for cardiovascular event reduction with GLP-1RA therapy in patients with obesity.
Claim CE Credit at https://bit.ly/3OkYJm9
-
Conversation around current considerations for use of GLP-1 RAs in people with type 2 diabetes and chronic kidney disease (CKD). The discussion will include general considerations for management of diabetes in CKD, potential benefits of GLP-1 RA therapy in CKD (e.g., glycemic lowering, CV risk reduction, potential kidney benefits), and a discussion of contemporary guideline recommendations for GLP-1 RA use in this population.
Claim CE and MOC Credit at https://bit.ly/4aNc3t8
-
Conversation around specific cardiovascular risks, while distinguishing between glycemic control and cardiovascular risk reduction. We will also highlight the benefits of treatment with GLP-1 RA in patients with diabetes.
Claim CE and MOC Credit at https://bit.ly/3SbyErW
-
This activity focuses on the American Heart Association’s Essential 8 and glucose control. You will learn how GLP-1 RAs accelerate these glucose control goals and contribute to cardiorenal outcomes including how they work.
Claim CE and MOC Credit at https://bit.ly/48J3MVh
-
HCM experts discuss the importance of shared decision-making in the treatment of patients with HCM with or at risk for arrhythmias, including patient perspectives. The prevalence of symptomatic and asymptomatic atrial fibrillation requires shared decision-making between patients and providers regarding initiation of oral anticoagulation and global management strategy (rate vs rhythm control). Likewise, this episode will highlight factors to consider when deciding on ICD placement, particularly for primary prevention of sudden cardiac death.
-
When patients present with symptoms such as fatigue, fainting, shortness of breath, chest pain or heart palpitations without a known cause, suspect and test for HCM. In this episode, experts will discuss the best approaches for the management of symptoms in patients with HCM. Lean more on identifying strategies to improve provider-patient communication and utilizing shared decision-making to personalize treatment strategies.
Claim CE and MOC Credit at bit.ly/HCM_Managing_Symptoms
-
In this episode, a panel of experts discuss identifying appropriate risk assessment strategies to accurately determine the level of VTE risk for patients.
Claim CE and MOC Credit at https://bit.ly/VTE2
-
People with HCM may need to make lifestyle changes, such as limiting their activity, to accommodate their disease. In this episode, experts will cover behavior modifications for patient with hypertrophic cardiomyopathy, including regular physical activity recommendations as well as sports participation, occupational considerations, pregnancy, and management of comorbidities.
Claim CE and MOC Credit at https://bit.ly/HCM_Lifestyle
-
HCM is a chronic and progressive disease that puts patients at risk of serious complications and co-morbidities. Early detection, disease and symptom management may help improve HCM outcomes. Learn tips and tricks for the initial diagnosis of Hypertrophic Cardiomyopathy, diagnostic testing, and referrals.
Claim CE and MOC Credit at bit.ly/HCM_Symptoms
-
Experts discuss the epidemiology of venous thromboembolism (VTE), including identifying patients at risk and discussing methods for the accurate diagnosis of DVT/PE as well as existing VTE treatment options, algorithms, and corresponding safety and efficiency profiles.
Claim CE and MOC Credit athttps://bit.ly/VTE1
-
HeartBEATS from Lifelong Learning™ Science Series is a podcast series curated by the AHA. Experts explore highlights on the most up-to-date information to inform your clinical practice. This episode discusses the epidemiology, pathophysiology, and how to manage atrial fibrillation in heart failure with reduced ejection fraction (HFrEF).
-
Listen to a podcast discussion on the impact of obesity in CVD, heart failure, and arrhythmia outcomes.
- Visa fler
